The nutritional status, serum lipids, protein, Ca, and Zn of 85 toxemic and 42 normal pregnant women were estimated longitudinally from the first trimester to delivery. The results of dietary survey revealed that correlative and regressive relationship closely existed between serum TC, LDL-C, LDL-C/HDL-C, AI, and percentage of animal fat. In the toxemic cases, there were significant increases of serum LDL-C/HDL-C, AI, and decrease of HDL-C, HDL-C/TC and Ca in the 1st trimester as compared with those of the normal. In the 3rd trimester, there were significant increases of serum TG, TC, LDL-C, LDL-C/HDL-C, AI and MUFA, and decrease of serum HDL-C, HDL-C/TC, Ca, Zn, total protein and albumin in the toxemic cases. The regressive relationship was found between GI (ges-tosis index) and serum Ca in the 1st trimester or GI and serum P/S, A/G, LDL-C/HDL-C, AI in 3rd trimester. The problem of nutritional factors on development of toxemic cases was discussed and some nutritional suggestions were made.

The nutritional status, serum protein, albumin, calcium, zinc, iron, SF, FEP, vitamin A, activity of RBC transketolase, and blood glutathione redu-ctase of 349 normal primigravidas, 30 healthy non-pregnant women and 42 toxemic gravidas were estimated longitudinally from the 1st trimester to delivery. It was noted that serum protein, albumin, Ca, Zn, and Fe decreased markedly in the course of pregnancy. The content of serum vitamin A showed no variation or decrease in the 3rd trimester in 1/3 of the pregnant women observed. Insufficiency of thiamine and riboflavin were noted in 16.7% and 47% of the normal pregnant women respectively. The adequate nutrients intakes in pregnancy were considered to be: Energy, +200 kcal/d; Protein, + 15g/d in the 2nd trimester and +25g/d in the 3rd trimester; Calcium 1000 mg/d in the 2nd trimester and 1500mg/d in the 3rd trimester; Zinc, 20mg/d; Iron 26 or 30 mg/d by supplementation if possible; vitaminA 1000 ?gRE/d; both thiamine and riboflavin 1.8 mg/d.

Humans ; Hematopoietic Stem Cell Transplantation ; Multiple Myeloma/therapy* ; Transplantation, Autologous ; Retrospective Studies ; Combined Modality Therapy ; Stem Cell Transplantation/adverse effects*